cogan's syndrome
Recently Published Documents


TOTAL DOCUMENTS

229
(FIVE YEARS 18)

H-INDEX

24
(FIVE YEARS 2)

Author(s):  
Debashis Maikap ◽  
Amrita Pradhan ◽  
Prasanta Padhan

Abstract Cogan’s syndrome (CS) is a rare autoimmune vasculitis of unknown aetiology characterised by non-syphilitic interstitial keratitis, audio-vestibular symptoms, sometimes systemic symptoms and multi-organ involvement. Atypical CS has other ocular features such as scleritis, episcelritis, retinitis and optic neuritis. Diagnosis of CS is purely clinical without a confirmatory test. Hereby, we report a case of atypical CS presenting with features of encephalitis who was treated successfully with intravenous pulse methylprednisolone with cyclophosphamide. It is important to consider Cogan’s syndrome in the differential diagnosis of encephalitis with ocular and vestibular symptoms in young patients, as high morbidity and mortality rates are effectively lowered by early immunosuppressive treatment.


2021 ◽  
Vol 64 (12) ◽  
pp. 943-948
Author(s):  
Jungmin Ahn ◽  
Brian Kim ◽  
Kyoung Rai Cho ◽  
Young-Soo Chang

Cogan’s syndrome is a rare inflammatory disease characterized by non-syphilitic keratitis and vestibulo-auditory symptoms including hearing loss, tinnitus, and vertigo. Although its precise pathogenesis is not known, Cogan’s syndrome is generally considered an autoimmune disease. This hypothesis is supported by the frequently successful remission of hearing loss after steroid administration and the association with other autoimmune disorders such as rheumatoid arthritis. Medical treatment of Cogan’s syndrome depends on disease severity and on how extensive the disease is. The involvement of inner ear pathology requires systemic corticosteroid therapy. In cases of treatment failure or the need for a corticosteroid-sparing effect, other immunosuppressive drugs can be used. We experienced two patients with typical Cogan’s syndrome, presenting bilateral progressive sensorineural hearing loss and dizziness with ocular involvement, which we have successfully treated with systemic steroid administration and immunosuppressive therapy.


2021 ◽  
Vol 11 ◽  
Author(s):  
Nils Venhoff ◽  
Jens Thiel ◽  
Markus A. Schramm ◽  
Ilona Jandova ◽  
Reinhard E. Voll ◽  
...  

Cogan’s syndrome is a rare autoimmune disease characterized by ocular inflammation and audiovestibular manifestations. Treatment consists of systemic glucocorticoids and other immunosuppressive agents including methotrexate, cyclophosphamide and TNF-α-inhibitors. Due to potential ovarian or fetal toxicity immunosuppressive treatment options are limited during pregnancies. Thus far there is a paucity of reports on pregnancies in Cogan’s syndrome. With minimal transplacental transfer, Certolizumab pegol is considered to be safe for the use in pregnant patients with underlying inflammatory diseases. However, there is no literature on the use of this TNF-α-inhibitor in Cogan’s syndrome in general and especially during gestation. Here we report three pregnancies in two Cogan’s Syndrome-patients treated with Certolizumab pegol. Treatment with Certolizumab pegol was effective and well tolerated in patients with Cogan’s syndrome and seems to be a safe treatment option during pregnancy.


2021 ◽  
Vol 1 (2) ◽  
pp. 256
Author(s):  
Carlos Rocha-de-Lossada ◽  
Barbara Romero-Nuñez ◽  
Noelia Sabater-Cruz ◽  
Jorge Peraza-Nieves ◽  
Josep Torras Sanvicens

Author(s):  
N Kougkas ◽  
G Bertsias ◽  
R Stratoudaki ◽  
N Avgoustidis

Hepatology ◽  
2020 ◽  
Author(s):  
Susanne Hafner ◽  
Thomas Seufferlein ◽  
Alexander Kleger ◽  
Martin Müller

2020 ◽  
Vol 59 (15) ◽  
pp. 1899-1904
Author(s):  
Satoshi Morinaka ◽  
Yohei Takano ◽  
Hiroto Tsuboi ◽  
Daisuke Goto ◽  
Takayuki Sumida

2020 ◽  
Vol 20 (9) ◽  
Author(s):  
Gabriela Mabel Espinoza ◽  
Joseph Wheeler ◽  
Katherine K. Temprano ◽  
Angela Prost Keller

Sign in / Sign up

Export Citation Format

Share Document